Melanie Chesnut
Nurse Practitioner · Barbourville, KYNPI 1578756821
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.9%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 22.7%. Among nurse practitioner clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 780 payments — averaging $26.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$5K
- Madrigal Pharmaceuticals$4K
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Johnson & Johnson$1K
- AstraZeneca$1K
- plus $6K from 26 others
What the payments were for
- Consulting fees$5,56127%
- Speaking & faculty fees$1,4007%
- Travel & lodging$1,2116%
- Food & beverage$12,33159%
- Education$4462%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 22 | $4,747 |
| Madrigal Pharmaceuticals | 31 | $3,564 |
| AbbVie | 125 | $3,117 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 110 | $1,329 |
| Johnson & Johnson | 61 | $1,157 |
| AstraZeneca | 28 | $1,015 |
| Lilly USA, LLC | 58 | $729 |
| Gilead | 43 | $658 |
| Biohaven Pharmaceuticals, Inc. | 22 | $522 |
| Novo Nordisk | 44 | $510 |
| Phathom Pharmaceuticals, Inc. | 38 | $490 |
| Bayer | 25 | $468 |
| Sanofi | 20 | $386 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $362 |
| Amgen | 23 | $315 |
| Pfizer | 18 | $249 |
| Sanofi-aventis U.S. LLC | 15 | $232 |
| Regeneron Healthcare Solutions, Inc. | 10 | $209 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $165 |
| Amarin Pharma, Inc. | 11 | $158 |
| Daiichi Sankyo Inc. | 9 | $142 |
| Ardelyx, Inc. | 6 | $116 |
| GSK | 5 | $80 |
| Novartis | 3 | $54 |
| Exact Sciences | 3 | $45 |
| Boehringer Ingelheim | 3 | $39 |
| Averitas Pharma Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,949 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 14 | $386,594 |
| EpclusaSofosbuvir/Velpatasvir | 11 | $259,626 |
| RezdiffraResmetirom | 18 | $196,535 |
| XifaxanRifaximin | 53 | $171,635 |
| CreonLipase/Protease/Amylase | 68 | $153,447 |
| RinvoqUpadacitinib | 15 | $122,195 |
| EliquisApixaban | 142 | $113,459 |
| OzempicSemaglutide | 104 | $113,150 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 172 | $110,264 |
| MounjaroTirzepatide | 90 | $100,120 |
| JardianceEmpagliflozin | 115 | $99,933 |
| RybelsusSemaglutide | 76 | $96,153 |
| EntrestoSacubitril/Valsartan | 94 | $79,997 |
| LinzessLinaclotide | 96 | $69,376 |
| FarxigaDapagliflozin Propanediol | 88 | $65,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,157 | $386,59414 claims |
| AbbVieCreon, Rinvoq, Linzess | $3,117 | $345,018179 claims |
| GileadEpclusa, Vemlidy | $658 | $304,25143 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Tezspire | $1,015 | $229,098272 claims |
| Novo NordiskOzempic, Rybelsus | $510 | $209,303180 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,329 | $201,373104 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Trijardy Xr, Combivent Respimat | $39 | $200,718266 claims |
| Madrigal PharmaceuticalsRezdiffra | $3,564 | $196,53518 claims |
| Lilly USA, LLCMounjaro, Trulicity | $729 | $136,877121 claims |
| PfizerEliquis, Nurtec Odt | $249 | $134,100161 claims |
| NovartisEntresto | $54 | $79,99794 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $232 | $47,33149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Barbourville
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
- Scott SeitzWinchester$34K
- Kristen KreinestEdgewood$34K
- Lillian ArgentEdgewood$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.